GENFIT is a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions in areas of high unmet medical needs corresponding to a lack of suitable treatment. GENFIT’s R&D efforts are focused on bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver and more generally the gastro-intestinal arena. GENFIT’s lead proprietary compound, elafibranor, is currently being evaluated in the phase III study “RESOLVE-IT” in NASH and in a phase II study in PBC.
DDW Tracks Microbiome in Gastrointestinal and Liver Diseases, Inflammatory Bowel Diseases, Liver Diseases and Transplantation, Esophageal Diseases, Stomach and Small Bowel Disorders, Colorectal Diseases, Functional GI and Motility Disorders, Pancreatic Diseases, Biliary Tract Diseases
Does your company only service US attendees? No
Is your company a new exhibiting company? No